Overview

This trial is active, not recruiting.

Condition myeloma
Treatments minocycline, placebo, questionnaires
Phase phase 2
Sponsor M.D. Anderson Cancer Center
Collaborator National Cancer Institute (NCI)
Start date March 2013
End date March 2019
Trial size 88 participants
Trial identifier NCT01793051, 2012-0413, NCI-2013-00700, P01CA124787

Summary

The goal of this clinical research study is to learn if minocycline can help reduce the symptoms reported by patients with MM who receive therapy with lenalidomide.

Minocycline is an antibiotic and has been shown to interrupt pro-inflammatory cytokine production, which may help to reduce multiple symptoms.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, investigator)
Primary purpose treatment
Arm
(Experimental)
Minocycline 200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance chemotherapy for MM. Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
minocycline Dynacin
200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.
questionnaires Surveys
Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
(Placebo Comparator)
Placebo 200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy). Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
placebo Sugar pill
200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).
questionnaires Surveys
Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.

Primary Outcomes

Measure
Symptom Reduction
time frame: Baseline to 3 months (three cycles with assessments made at beginning of each)

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Patients with pathologically diagnosed who have received induction chemotherapy, with or without AuSCT, and who have qualified to receive lenalidomide-based maintenance therapy for their MM. 2. Patients > or = 18 years old. 3. Patients able to render informed consent and to follow protocol requirements. 4. Patients who speak English (due to patient-reported outcome language options, we are only accruing English-speaking patients to the protocol). 5. Patients with normal renal function according to MD Anderson testing standards and no prior renal disease [screening cut off for serum creatinine < 1.5 times the upper limit of normal]. 6. Patients with normal hepatic function according to MD Anderson testing standards and no prior liver disease [screening results for total bilirubin must be < 1.5 times the upper limit of normal; screening results for alkaline phosphatase (ALP) and alanine aminotransferase (ALT) must be < 2 times the upper limit of normal; if available, screening results for aspartate aminotransferase (AST) must be < 2 times the upper limit of normal]. Exclusion Criteria: 1. Patients who are taking minocycline for other conditions, as determined by the treating physician 2. Patients with hypersensitivity to tetracyclines 3. Women who are pregnant or nursing; pregnancy will be confirmed by urine test 4. Patients who are enrolled in other clinical trials that have symptom management as primary outcome 5. Patients who are not able to use telephone-based interactive voice response software due to physical limitations (e.g., impaired hearing) 6. Patients taking any tetracycline in the last 15 days 7. Patients on Vitamin K antagonist warfarin

Additional Information

Official title A Phase II Randomized Study of the Efficacy of Minocycline vs. Placebo to Reduce Symptom Burden During Maintenance Therapy for Multiple Myeloma
Principal investigator Robert Orlowski, MD, PHD
Description Study Groups: If you agree to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 groups. Group 1 will take a placebo during maintenance therapy. Group 2 will take minocycline during maintenance therapy. A placebo is not a drug. It looks like the study drug but it is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect. Neither you nor the study staff will know if you are receiving the study drug or the placebo. However, if needed for your safety, the study staff will be able to find out what you are receiving. Study Drug Administration: You will take the study drug/placebo by mouth, two times a day for about 3 months, starting the first day (or within 2 days) that you begin your lenalidomide therapy. You should take the study drug/placebo with a full glass (8 ounces) of water. You may take it with or without food, but if the study drug/placebo causes an upset stomach, you should take it with food. You check with the study doctor about continuing any drugs you are currently taking. The study drug may not mix well with other drugs. You should not take bismuth (Pepto-Bismol), calcium, iron, magnesium, zinc, multivitamins with minerals, colestipol, cholestyramine, didanosine, and/or antacids within 2 hours of taking the study drug. You should also avoid alcohol (including wine, beer, and liquor), driving, and doing other tasks or activities until you learn how the study drug affects you. Study Visits: You must bring the study drug/placebo container, along with any remaining drug, with you to your clinic visit at each new cycle of lenalidomide therapy, or at the clinic visit when the study is over if no clinic visits are scheduled until then. Before you start lenalidomide therapy: - You will fill out 4 questionnaires about pain and other symptoms. It should take about 20-25 minutes to complete all of the questionnaires. - A study staff member will ask you questions about your demographic information, such as your marital status, job status, education, and race. - Blood (about 2 tablespoons) will be drawn for biomarker testing. This will be during an already scheduled blood draw and you would not need to have an extra needle stick. Biomarkers are found in the blood/tissue and may be related to your reaction to the study drug. Researchers want to study how changes in the biomarkers may be related to the symptoms reported by participants in this study. During lenalidomide therapy: °You will complete a symptom questionnaire in the clinic or by telephone 1 time each week about any symptoms you may be having and how they may be affecting your daily activities. The symptom questionnaire should take about 3-5 minutes to complete each time. During your clinic visit at each new cycle of lenalidomide therapy: - You will fill out 3 questionnaires about your pain and other symptoms. It should take about 15-20 minutes to complete all of the questionnaires each time. If no clinic visit is scheduled until the study is over, these questionnaires will be collected over the phone by the study coordinator. - Blood (about 2 tablespoons) will be drawn for biomarker testing. This will be during an already scheduled blood draw and you would not need to have an extra needle stick. End-of-Treatment Visit: You will have an end-of-treatment visit at the end of month 3. At this visit, you will complete 4 questionnaires about pain and other symptoms. It should take about 20-25 minutes to complete all of the questionnaires. Blood (about 2 tablespoons) will be drawn for biomarker testing. This will be during an already scheduled blood draw and you would not need to have an extra needle stick. Length of Study: You may continue taking the study drug/placebo for up to 3 months. You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, if you are unable to follow study directions, or the study doctor thinks it is in your best interest. This is an investigational study. Minocycline is FDA approved and commercially available for the treatment of bacterial infection. The use of minocycline to reduce chemotherapy related side effects in patients with MM is currently being used for research purposes only. Up to 88 patients will take part in this study. All will be enrolled at MD Anderson Cancer Center.
Trial information was received from ClinicalTrials.gov and was last updated in July 2016.
Information provided to ClinicalTrials.gov by M.D. Anderson Cancer Center.
Location data was received from the National Cancer Institute and was last updated in August 2016.